Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 3Recruiting 3Not yet recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 35Thoracic 10Head & Neck 3Lymphoid 2Gynecologic 2Breast 2Other solid neoplasm 1Genitourinary 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16trastuzumab deruxtecan 15Docetaxel 15Radiotherapy 13Standard of Care 12Fulvestrant 12Drug Therapy 12dalpiciclib 11Letrozole 11pembrolizumab 9Epirubicin 9sacituzumab govitecan 8palbociclib 8exemestane 8eribulin 8Anastrozole 8Injections 7Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Specimen Handling 6Neoadjuvant Therapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × sintilimab × Breast × Clear all
NCT07254858 2025-11-28

CISN-L

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
302 enrolled
Breast

Breast Neoplasms

NCT06308939 2024-03-13

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
81 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡